Santin, A. D., Fader, A., Roque, D. M., Eric, S., Buza, N., Pei, H., … Schwartz, P. (2017). Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002). In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (Vol. 27, pp. 15–16). LIPPINCOTT WILLIAMS & WILKINS.

Santin, A. D., A. Fader, D. M. Roque, S. Eric, N. Buza, H. Pei, O. Abdelghany, et al. “Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002).” In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 27:15–16. LIPPINCOTT WILLIAMS & WILKINS, 2017.

Santin AD, Fader A, Roque DM, Eric S, Buza N, Pei H, et al. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002). In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. LIPPINCOTT WILLIAMS & WILKINS; 2017. p. 15–6.

Santin, A. D., et al. “Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002).” INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 27, LIPPINCOTT WILLIAMS & WILKINS, 2017, pp. 15–16.

Santin AD, Fader A, Roque DM, Eric S, Buza N, Pei H, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Elena R, Silasi DA, Schwartz P. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002). INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. LIPPINCOTT WILLIAMS & WILKINS; 2017. p. 15–16.